Miguel Montoro

TL;DR: As many as 1 of 4 patients on thiopurine therapy had adverse events during follow-up, with the cumulative incidence of adverse events being 26%, with an annual risk of 7% per patient-year of treatment.

TL;DR: Concomitant therapy led to a non-statistically significant advantage (5%) over sequential therapy, coming closer to 90% cure rates, and both therapies showed an acceptable safety profile.

TL;DR: The clinical presentation of CI is very heterogeneous, perhaps explaining why clinical suspicion of this disease is so low and the presence of IRCI, and occurrence of peritoneal signs or onset of CI as severe abdominal pain without bleeding, should alert the physician to a potentially unfavorable course.

TL;DR: The consumption of drugs, current smoking, and associated autoimmune diseases were independently associated with the risk of microscopic colitis.

TL;DR: Evaluating the long-term durability of maintenance infliximab treatment in patients with Crohn's disease found a high proportion of CD patients initially respond to inflIXimab dose escalation, and concurrent immunomodulators may increase and smoking may decrease maintenance of response.